Media & Resources

PedMab1-Ex, led by SAMRC and Ospedale San Raffaele, aims to assess ePGT121v1-LS for eventual use to prevent HIV acquisition by infants and young children.

New study published in Nature shows for the first time elicitation of broadly neutralizing antibodies to HIV in a stringent animal model.

IAVI harnesses its prowess in antibody isolation, engineering, and optimization to expand its portfolio of vaccines and monoclonal antibodies against multiple bacterial pathogens.

MTBVAC AVANTE offers crucial support to advance ongoing clinical trials in sub-Saharan Africa.

Celebrating the launch of landmark clinical trials IAVI G004, IAVI C114, and BRILLIANT 011.

The trial, run by the HIV Vaccines Trial Network (HVTN) and HIV Prevention Trials Network (HPTN), will evaluate the safety, dosing, pharmacokinetics, and ability of four bnAbs to neutralize HIV

Updates on IAVI’s advocacy, communications, and programs to advance TB vaccines

Additional enrollment of 1,200 participants could ultimately enable a fast track to licensure